Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-461-2315
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees11
Next Earnings Date6/12/2019 (Estimated)
OptionableOptionable
Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions
What is Tyme Technologies' stock symbol?
Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."
How were Tyme Technologies' earnings last quarter?
Tyme Technologies Inc (NASDAQ:TYME) issued its earnings results on Monday, February, 11th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. View Tyme Technologies' Earnings History.
When is Tyme Technologies' next earnings date?
What price target have analysts set for TYME?
2 brokers have issued 12-month target prices for Tyme Technologies' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Tyme Technologies' stock price to reach $10.00 in the next year. This suggests a possible upside of 571.1% from the stock's current price. View Analyst Price Targets for Tyme Technologies.
What is the consensus analysts' recommendation for Tyme Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.
What are Wall Street analysts saying about Tyme Technologies stock?
Here are some recent quotes from research analysts about Tyme Technologies stock:
- 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (4/17/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030 assuming a 12% discount rate and 2% terminal growth rate." (11/7/2018)
- 3. Canaccord Genuity analysts commented, "We continue to view SM-88’s ability to generate responses across ~15 solid and liquid tumor types and with durable effect in advanced cancer patients progressing on available therapies as intriguing and reiterate our BUY rating." (6/15/2018)
Has Tyme Technologies been receiving favorable news coverage?
Media coverage about TYME stock has been trending somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tyme Technologies earned a news impact score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next several days.
Who are some of Tyme Technologies' key competitors?
Some companies that are related to Tyme Technologies include DiaMedica Therapeutics (DMCAF), Lexicon Pharmaceuticals (LXRX), Viking Therapeutics (VKTX), Odonate Therapeutics (ODT), Obseva (OBSV), Dermira (DERM), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), Revance Therapeutics (RVNC), Forty Seven (FTSV), ZEALAND PHARMA/S (ZEAL), Aurinia Pharmaceuticals (AUPH), Synthorx (THOR), OvaScience (OVAS) and Stemline Therapeutics (STML).
What other stocks do shareholders of Tyme Technologies own?
Who are Tyme Technologies' key executives?
Tyme Technologies' management team includes the folowing people:
- Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)
- Mr. Ben R. Taylor, Pres & CFO (Age 42)
- Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)
- Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)
- Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57)
Who are Tyme Technologies' major shareholders?
Tyme Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (0.08%). Company insiders that own Tyme Technologies stock include Douglas A Michels, Michael Demurjian and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies.
Which major investors are selling Tyme Technologies stock?
TYME stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. Company insiders that have sold Tyme Technologies company stock in the last year include Michael Demurjian and Steve Hoffman. View Insider Buying and Selling for Tyme Technologies.
How do I buy shares of Tyme Technologies?
Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tyme Technologies' stock price today?
One share of TYME stock can currently be purchased for approximately $1.49.
How big of a company is Tyme Technologies?
Tyme Technologies has a market capitalization of $154.66 million. The company earns $-18,960,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.
What is Tyme Technologies' official website?
How can I contact Tyme Technologies?
Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]
MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
